The role of the pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC) is to assess the clinical evidence and cost-effectiveness of cancer drugs in order to make recommendations to the provinces and territories to help guide their drug funding decisions.
A submission for the assessment of a cancer drug may be made by a pharmaceutical manufacturer and/or a provincially recognized clinician-based tumour group from the provinces or territories. For each cancer drug assessed, pERC looks at all of the information related to the committee's deliberative framework.
pERC may also receive submissions or requests for advice from the pCODR Provincial Advisory Group or the Pharmaceutical Advisory Committee. These submissions or requests regarding a new drug may be related to its clinical or cost-effectiveness in comparison to existing therapies.
Recommendations for drug products that may be considered for funding are provided to the provincial or territorial Ministries of Health and provincial cancer agencies, along with the reasons why the recommendation has been made. The recommendations and the reasoning behind them are also available to the public.
CADTH, in collaboration with the participating jurisdictions and with input from stakeholders, has established a single recommendation framework to support its drug expert committees in making recommendations to the participating jurisdictions to guide their reimbursement decisions. The Recommendation Framework for CADTH Common Drug Review and pan-Canadian Oncology Drug Review Programs highlight some of the factors that CADTH’s drug expert committees, in formulating a reimbursement recommendation, will consider to provide guidance to the participating jurisdictions.
All members of pERC must comply with the following:
- pCODR Conflict of Interest (COI) Guidelines Last updated: October 30, 2020
- pCODR Code of Conduct Last updated: March 2018
- pCODR Expert Review Committee (pERC) Terms Of Reference Last updated: June 25, 2020
pERC's Deliberative Framework
To ensure the consistency and transparency of its cancer drug review process, pERC follows a well-defined deliberative framework. This framework describes all the elements that should be considered by pERC during its review.
Each element is important to the review, and it is the sum consideration of all elements that pERC uses to formulate a funding recommendation.
- Deliberative Framework Last updated: March 2011
All pERC members have experience with and a good understanding of issues related to cancer diagnosis, treatment, and care. Each member must also comply with CADTH's conflict of interest, confidentiality requirements, and code of conduct. Professional members of pERC are drawn from the fields of medicine, pharmacy, pharmacology, or health economics. Patient members are selected because of their personal knowledge of, experience with, and understanding of issues related to cancer and its management, among other qualifications. pERC has up to 17 voting members including the three patient members.
- Dr. Kelvin Chan, Economist | Bio | COI
- Dr. Anil Abraham Joy, Oncologist (term expired December 31, 2020) | Bio | COI
- Dr. Matthew Cheung, Oncologist | Bio | COI
- Valerie McDonald, Patient Member | Bio | COI
- Marianne Taylor, Oncologist | Bio | COI
- Leela John, Pharmacist | COI
- Cameron Lane, Patient | Bio | COI
- Dr. Winson Cheung, Oncologist | Bio | COI
- Dr. Avram Denburg, Oncologist/Ethics expertise | Bio | COI
- Dr. Christine Kennedy, Non-Oncology Physician | Bio | COI
- Christopher Longo, Health Economist | Bio | COI
- Dr. Christian Kollmannsberger, Oncologist | Bio | COI
- Dominika Wranik, Economist | COI
- Daryl Bell, Patient Alternate | COI
- Dr. Michael Crump, Oncologist | COI
- Dr. Jennifer Bell, Ethicist | Bio | COI